MRA-661杂交瘤17.4抗伯氏疟原虫红细胞膜蛋白Pb(em)-46(细胞库)
产品图片

货号/SKU
MRA-661
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质,其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类:美国、1
产品描述信息
MRA-661?? Hybridoma 17.4 Anti-Plasmodium berghei Erythrocyte Membrane Protein Pb(em)-46(Cell Banks)|Plasmodium berghei|Hybridoma 17.4 Anti-Plasmodium berghei Erythrocyte Membrane Protein Pb(em)-46|-100°C or colder, preferably in the vapor phase of a liquid nitrogen freezer|MF WiserAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Hybridoma 17.4 Anti-Plasmodium berghei Erythrocyte Membrane Protein Pb(em)-46, MRA-661, contributed by Mark F. Wiser.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
The murine hybridoma cell line, 17.4, was generated by the fusion of X63Ag8.653 mouse myeloma cells with splenocytes from mice immunized with purified Plasmodium berghei (P. berghei) erythrocyte membrane protein, Pb(em)-46. Pb(em)-46 is a 46-kDa phosphoprotein associated with the submembrane cytoskeleton of P. berghei-infected erythrocytes. The original hybridoma was described as 17.2; hybridoma 17.4 produces a monoclonal antibody of the same specificity, but has better growth characteristics.
Hybridoma 17.4 produces monoclonal antibody of IgG1 subclass that specifically recognizes an approximately 46-kDa phosphoprotein found on the P. berghei-infected erythrocyte membrane. The antibody is reported to function in immunoblotting and immunofluorescence assays.
Each vial contains approximately 0.5 mL of hybridoma cells in cell culture medium supplemented with 10% dimethylsulfoxide (DMSO) at a concentration of 107 cells per mL. Sufficient cells are provided to initiate at least one new culture.
The murine hybridoma cell line, 17.4, was generated by the fusion of X63Ag8.653 mouse myeloma cells with splenocytes from mice immunized with purified Plasmodium berghei (P. berghei) erythrocyte membrane protein, Pb(em)-46. Pb(em)-46 is a 46-kDa phosphoprotein associated with the submembrane cytoskeleton of P. berghei-infected erythrocytes. The original hybridoma was described as 17.2; hybridoma 17.4 produces a monoclonal antibody of the same specificity, but has better growth characteristics.
Hybridoma 17.4 produces monoclonal antibody of IgG1 subclass that specifically recognizes an approximately 46-kDa phosphoprotein found on the P. berghei-infected erythrocyte membrane. The antibody is reported to function in immunoblotting and immunofluorescence assays.
Each vial contains approximately 0.5 mL of hybridoma cells in cell culture medium supplemented with 10% dimethylsulfoxide (DMSO) at a concentration of 107 cells per mL. Sufficient cells are provided to initiate at least one new culture.
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.在此限制上订单将在发货前发送至NIAID进行批准.
鼠杂交瘤细胞系17.4,通过X63AG8.653小鼠骨髓瘤细胞的融合产生,用纯化的纯化的小鼠免疫细鼠脾细胞(P. Berghei)(P. Berghei)/ i>红细胞膜蛋白,Pb(EM) - 46. Pb(EM)-46是与蒙皮骨架相关的46kDa磷蛋白为 p. Berghei -infed红细胞.原始杂交瘤描述为17.2;杂交瘤17.4产生具有相同特异性的单克隆抗体,但具有更好的增长特征.
杂交瘤17.4产生IgG1亚类的单克隆抗体,其特异性识别在 p上的约46kda磷蛋白. Berghei - 植物的红细胞膜.据报道,抗体在免疫印迹和免疫荧光测定中起作用.
每个小瓶在细胞培养基中含有大约0.5ml杂交瘤细胞,其补充有10%二甲基磺砜(DMSO),其浓度为每mL 10 7℃的细胞.提供足够的细胞以引发至少一种新培养物.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立,旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中,可以监控科学界对这些材料的访问和使用,并确保试剂的质量控制。
除了为传染病界提供材料外,BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势,包括安全存储、社区访问和分发;同时保护存款人的知识产权。只要有需要,BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月, ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料,包括由其他政府支持的研究项目存放的材料,将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中,涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识

可能感兴趣的内容
2024-02-29
2022-08-11
2021-12-21
2024-12-12
2022-04-01
2021-12-21
2024-05-19
2022-04-01
2021-12-02
2021-12-21
2022-04-01
2022-04-01
2021-12-21
2021-12-21
2021-12-21